3M, trading at $0.77 on the NASDAQ. This SniperIQ fundamentals page covers Estrella Immunopharma's valuation, profitability (net margin 0.0%), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap
3M
Net Margin0.0%

Full research coverage

Frequently Asked Questions

What is Estrella Immunopharma's market cap?

Estrella Immunopharma (ESLA) has a market capitalization of approximately

3M, trading at $0.77 on the NASDAQ. Market cap moves with the live share price.

How profitable is Estrella Immunopharma?

Estrella Immunopharma runs a net profit margin of 0.0%, a gross margin of 0.0%, and an operating margin of 0.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

Does Estrella Immunopharma pay a dividend?

Estrella Immunopharma does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Estrella Immunopharma financially healthy?

Estrella Immunopharma carries a debt-to-equity ratio of 0.00x and a current ratio of 0.24x, with a market beta of 0.86. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Estrella Immunopharma a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Estrella Immunopharma (ESLA) the key facts are: market cap

3M, 52-week range 0.73-3.15. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Estrella Immunopharma's full fundamentals live

Get Estrella Immunopharma's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.